Chidamide, Sintilimab, and Bevacizumab for Advanced Neuroendocrine Cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of three drugs—chidamide (a protein regulator), sintilimab (an immune-boosting antibody), and bevacizumab (a growth-blocking antibody)—for patients with advanced neuroendocrine cancer that has spread or cannot be removed surgically and has progressed despite an initial treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Confirmed diagnosis of advanced, unresectable, or metastatic extrapulmonary neuroendocrine carcinoma (cancer that starts outside the lungs)
- Cancer must have progressed or worsened during or after your first round of systemic treatment
- At least one measurable tumor visible on imaging scans
- Good overall health and functional ability (able to care for yourself with minimal assistance)
- Adequate blood counts, liver, and kidney function confirmed by recent blood tests
- Age 18–75 years with life expectancy of at least 12 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of an immunotherapy drug (QL1706), a targeted therapy (lenvatinib), and chemotherapy for people with advanced neuroendocrine carcinoma that started outside the lungs. The goal is to see if this combination can help shrink or slow the cancer.
This trial tests a combination of three drugs for people with advanced neuroendocrine carcinoma that has stopped responding to previous treatments. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a new drug (LBL-024) combined with standard chemo as a first treatment for a rare and fast-growing neuroendocrine cancer (EP-NEC) that started outside the lungs. It may offer a new option for people whose cancer has spread and who haven't had treatment yet.
This trial tests a combination of immunotherapy (benmelstobart), a targeted therapy (anlotinib), and chemotherapy as the first treatment for advanced neuroendocrine cancers that started in the lung or gut. It aims to see if this combo works better than standard chemo alone.
This trial tests a combination of chemotherapy (FOLFIRI) plus two immunotherapy drugs (zimberelimab and domvanalimab) for people with advanced neuroendocrine carcinoma that has grown after initial treatment. It aims to see if this new approach works better than standard chemotherapy alone.
This trial tests a new drug, LBL-024, combined with standard chemotherapy (etoposide and platinum) for people with advanced neuroendocrine carcinoma. The goal is to see if this combination works better than chemo alone.
Hear when a new Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.